Quarry LP Boosts Stake in Xencor, Inc. (NASDAQ:XNCR)

Quarry LP lifted its holdings in Xencor, Inc. (NASDAQ:XNCR) by 111.4% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 4,000 shares of the biopharmaceutical company’s stock after purchasing an additional 2,108 shares during the period. Quarry LP’s holdings in Xencor were worth $80,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Primecap Management Co. CA lifted its stake in Xencor by 0.3% in the 2nd quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock worth $172,570,000 after purchasing an additional 25,495 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Xencor by 147.3% during the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock worth $62,748,000 after buying an additional 1,858,440 shares in the last quarter. Logos Global Management LP boosted its stake in Xencor by 130.8% during the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after buying an additional 850,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Xencor by 6.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,459,427 shares of the biopharmaceutical company’s stock worth $27,628,000 after buying an additional 87,979 shares during the last quarter. Finally, Baker BROS. Advisors LP grew its holdings in Xencor by 22.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 670,431 shares of the biopharmaceutical company’s stock valued at $13,482,000 after buying an additional 125,000 shares in the last quarter.

Analyst Ratings Changes

XNCR has been the topic of several analyst reports. Royal Bank of Canada lifted their price target on Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. JPMorgan Chase & Co. lifted their target price on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $20.00 to $30.00 in a report on Monday, December 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $34.00 target price (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Finally, Wedbush restated an “outperform” rating and set a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $36.50.

Xencor Stock Performance

Shares of Xencor stock opened at $25.34 on Monday. Xencor, Inc. has a one year low of $15.31 and a one year high of $27.24. The company has a market cap of $1.77 billion, a PE ratio of -7.92 and a beta of 0.69. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The business has a 50-day simple moving average of $22.51 and a 200-day simple moving average of $20.60.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $10.70 million during the quarter, compared to the consensus estimate of $14.59 million. During the same period in the previous year, the company posted ($0.40) earnings per share. The business’s revenue for the quarter was down 81.9% on a year-over-year basis. On average, equities research analysts forecast that Xencor, Inc. will post -3.71 EPS for the current fiscal year.

Insider Activity at Xencor

In other Xencor news, Director Alan Bruce Montgomery sold 1,421 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the transaction, the director now owns 9,140 shares of the company’s stock, valued at approximately $247,054.20. This trade represents a 13.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of Xencor stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the transaction, the vice president now directly owns 200,104 shares in the company, valued at $4,698,441.92. The trade was a 25.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 136,050 shares of company stock valued at $3,277,609 over the last three months. 5.23% of the stock is owned by corporate insiders.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.